Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Rafael Fonseca MD

Rafael Fonseca MD

Chief Innovation Officer, Mayo Clinic; Getz Family Professor of Cancer, Professor of Medicine, Mayo Clinic School of Medicine, Phoenix, Arizona

Dr. Rafael Fonseca is the Getz Family Professor of Cancer, Professor of Medicine, Chief Innovation Officer, and a consultant in the Division of Hematology/Oncology at the Mayo Clinic in Arizona. He is a member of the Mayo Clinic Board of Governors and Board of Trustees.

Dr. Fonseca's practice has focused on the diagnosis and treatment of plasma cell disorders and leading the multiple myeloma team in its efforts to develop a better understanding of the disease and its impact on patients.

Throughout his training and career, Dr. Fonseca has received numerous awards and honors. Most notably, he is a Mayo Clinic Distinguished Investigator, the highest academic distinction given to investigators at his institution. Dr. Fonseca holds memberships and serves in positions for organizations such as the American Society of Clinical Oncology, American Society of Hematology, American Association for Cancer Research, and the International Myeloma Society.

Dr. Fonseca serves as reviewer and in editorial capacities for medical publications including Blood, The Lancet, Nature Medicine, Cancer Cell, Leukemia, and The New England Journal of Medicine, among others. He has given many national and international presentations as a visiting professor, and has authored numerous articles (over 300), book chapters, editorials, abstracts, and letters.

Disclosures

  • Consultant: AbbVie; Adaptive Biotechnologies; AMGEN; AstraZeneca; Bayer; Binding Site; BMS (Celgene); Millennium Takeda; Jansen; Juno;, Kite; Merck; Pfizer; Pharmacyclics; Regeneron; Sanofi.
  • Advisory Board: Adaptive Biotechnologies; Caris Life Sciences; ONCOtracker
  • Board of Directors: Antengene (for profit); AZBio (not for profit)
  • Patent for FISH in MM (~$2000/yr)

Recent Contributions to PracticeUpdate:

  1. Overall Survival Benefits of Cancer Drugs Initially Approved by the US FDA Based on Surrogate Endpoints
  2. ASCO 2024: Abstract Recommendations From Dr. Rafael Fonseca for Multiple Myeloma
  3. Association of Minimal Residual Disease Status 1 Year After Autologous HCT and Lenalidomide Maintenance With Long-Term Overall Survival in Multiple Myeloma
  4. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for Newly Diagnosed Transplantation-Eligible Multiple Myeloma
  5. Once-Weekly vs Twice-Weekly Bortezomib for Newly Diagnosed Multiple Myeloma
  6. Gilteritinib as Posttransplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3
  7. Teclistamab for Relapsed/Refractory Multiple Myeloma in the Real World
  8. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Tandem Transplant for High-Risk Newly Diagnosed Multiple Myeloma
  9. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
  10. Genomic Classification and Individualized Prognosis in Multiple Myeloma

Elsewhere

Most Read This Week

Recently Updated